-DOCSTART-	O

Title	O
:	O
The	B-I
maximal	I-I
double	I-I
step	I-I
length	I-I
test	I-I
can	O
evaluate	O
more	O
adequately	O
the	O
decrease	O
of	O
physical	O
function	O
with	O
age	O
,	O
than	O
the	B-I
maximal	I-I
single	I-I
step	I-I
length	I-I
test	I-I
.	O

METHODS	O
:	O
Fifty	B-P
-	I-P
seven	I-P
elderly	I-P
females	I-P
who	I-P
live	I-P
independently	I-P
(	I-P
age	I-P
74	I-P
.	I-P
85	I-P
.	I-P

6	I-P
years	I-P
)	I-P
were	O
recruited	O
.	O

MSL	B-I
and	O
MDSL	B-I
were	O
conducted	O
twice	O
after	O
completing	O
an	B-O
ADL	I-O
questionnaire	I-O
.	O

-DOCSTART-	O

Title	O
:	O
West	O
vs	O
.	O

West	O
like	O
East	O
vs	O
.	O

West	O
?	O
A	O
comparison	O
between	O
Italian	B-P
and	I-P
US	I-P
American	I-P
context	O
sensitivity	O
and	O
Fear	O
of	O
Isolation	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
pilot	O
study	O
of	O
the	B-I
Tele	I-I
-	I-I
Airway	I-I
Management	I-I
System	I-I
in	O
a	O
hospital	O
emergency	O
department	O
.	O

METHODS	O
:	O
In	O
a	O
pilot	O
study	O
we	O
examined	O
the	O
usefulness	O
of	O
the	B-I
TAMS	I-I
for	I-I
intubations	I-I
of	O
actual	B-P
patients	I-P
in	I-P
a	I-P
hospital	I-P
emergency	I-P
department	I-P
.	O

Twenty	B-P
-	I-P
five	I-P
patients	I-P
were	O
allocated	O
randomly	O
either	O
to	O
a	B-I
TAMS	I-I
group	O
or	O
to	O
an	B-I
on	I-I
-	I-I
scene	I-I
directed	I-I
(	I-I
OSD	I-I
)	I-I
group	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effects	O
of	O
parecoxib	B-I
on	O
morphine	O
dosage	O
in	O
postoperative	B-P
patient	I-P
-	I-P
controlled	I-P
analgesia	I-P
following	I-P
thoracoscope	I-P
-	I-P
assisted	I-P
thoracotomy	I-P
]	O
.	O

METHODS	O
:	O
A	B-P
consecutive	I-P
series	I-P
of	I-P
100	I-P
patients	I-P
undergoing	I-P
thoracoscope	I-P
-	I-P
assisted	I-P
thoracotomy	I-P
were	O
randomized	O
into	O
5	O
groups	O
and	O
received	O
PCA	O
with	O
morphine	O
doses	O
at	O
0	O
,	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
mg	O
given	O
in	O
200	O
ml	O
saline	O
(	O
groups	O
P	O
(	O
1	O
)	O
,	O
P	O
(	O
2	O
)	O
,	O
P	O
(	O
3	O
)	O
,	O
P	O
(	O
4	O
)	O
,	O
and	O
P	O
(	O
5	O
)	O
,	O
respectively	O
)	O
.	O

Parecoxib	B-I
(	O
40	O
mg	O
)	O
was	O
given	O
in	O
all	O
the	O
patients	O
immediately	O
before	O
the	O
operation	O
,	O
and	O
the	O
mixture	O
(	O
4	O
-	O
5	O
ml	O
)	O
of	O
lidocaine	O
and	O
ropivacaine	O
was	O
administered	O
into	O
the	O
3	O
intercostal	O
spaces	O
upper	O
and	O
lower	O
to	O
the	O
incision	O
before	O
chest	O
closure	O
.	O

PCA	O
was	O
administered	O
for	O
each	O
patient	O
.	O

The	B-O
visual	I-O
analogue	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
at	O
rest	O
and	O
coughing	O
and	O
the	B-O
respiratory	I-O
functional	I-O
parameters	I-O
were	O
recorded	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
24	O
,	O
36	O
,	O
and	O
48	O
h	O
after	O
the	O
start	O
of	O
PCA	O
,	O
and	O
the	O
actual	O
and	O
effective	O
button	O
-	O
pressing	O
times	O
(	O
D	O
(	O
1	O
)	O
/	O
D	O
(	O
2	O
)	O
)	O
in	O
PCA	O
were	O
also	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Presentation	O
of	O
a	O
randomized	O
multicenter	O
study	O
protocol	O
.	O

"	O
Evaluation	O
of	O
adjuvant	B-I
interferon	I-I
effectiveness	O
after	O
radical	O
nephrectomy	O
in	O
kidney	O
carcinoma	O
with	O
high	O
risk	O
of	O
relapse	O
"	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Fecal	O
butyrate	O
levels	O
vary	O
widely	O
among	O
individuals	O
but	O
are	O
usually	O
increased	O
by	O
a	B-I
diet	I-I
high	I-I
in	I-I
resistant	I-I
starch	I-I
.	O

METHODS	O
:	O
To	O
examine	O
variation	O
in	O
fecal	B-O
variables	I-O
,	O
especially	O
butyrate	B-O
,	O
among	O
individuals	O
and	O
the	O
response	O
to	O
these	O
fibers	O
,	O
a	O
randomized	O
cross	O
-	O
over	O
study	O
was	O
conducted	O
that	O
compared	O
the	O
effects	O
of	O
foods	B-I
supplying	I-I
25	I-I
g	I-I
of	I-I
NSP	I-I
or	O
25	B-I
g	I-I
of	I-I
NSP	I-I
plus	O
22	B-I
g	I-I
of	I-I
RS	I-I
/	I-I
d	I-I
over	O
4	O
wk	O
in	O
46	B-P
healthy	I-P
adults	I-P
(	I-P
16	I-P
males	I-P
,	I-P
30	I-P
females	I-P
;	I-P
age	I-P
31	I-P
-	I-P
66	I-P
y	I-P
)	I-P
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
pain	B-I
-	I-I
free	I-I
treadmill	I-I
training	I-I
on	O
fibrinogen	O
,	O
haematocrit	O
,	O
and	O
lipid	O
profile	O
in	O
patients	B-P
with	I-P
claudication	I-P
.	O

METHODS	O
:	O
Randomized	O
control	O
trial	O
.	O

Sixty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
peripheral	I-P
obstructive	I-P
arterial	I-P
disease	I-P
and	I-P
intermittent	I-P
claudication	I-P
(	I-P
Fontaine	I-P
stage	I-P
II	I-P
)	I-P
were	O
randomly	O
assigned	O
into	O
the	B-I
treadmill	I-I
training	I-I
(	O
repetitive	O
intervals	O
to	O
onset	O
of	O
claudication	O
pain	O
,	O
three	O
times	O
a	O
week	O
)	O
or	O
a	O
control	O
group	O
(	O
no	B-C
change	I-C
in	I-C
physical	I-C
activity	I-C
)	O
over	O
3	O
months	O
.	O

Both	O
groups	O
performed	O
treadmill	O
test	O
to	O
assess	O
pain	B-O
-	I-O
free	I-O
walking	I-O
time	I-O
(	I-O
PFWT	I-O
)	I-O
and	O
maximal	B-O
walking	I-O
time	I-O
(	I-O
MWT	I-O
)	I-O
and	O
had	O
blood	B-O
analyses	I-O
[	O
for	O
haematocrit	B-O
,	O
fibrinogen	B-O
,	O
triglycerides	B-O
,	O
and	O
cholesterol	B-O
:	O
total	B-O
,	I-O
high	I-O
-	I-O
density	I-O
lipoprotein	I-O
(	I-O
HDL	I-O
)	I-O
and	O
low	B-O
-	I-O
density	I-O
lipoprotein	I-O
(	I-O
LDL	I-O
)	I-O
]	O
done	O
at	O
baseline	O
and	O
after	O
6	O
and	O
12	O
weeks	O
of	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Improving	O
emotion	O
regulation	O
with	O
CBT	B-I
in	O
young	B-P
children	I-P
with	I-P
high	I-P
functioning	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
Eleven	B-P
5	I-P
-	I-P
7	I-P
year	I-P
-	I-P
old	I-P
children	I-P
participated	O
in	O
a	B-I
CBT	I-I
-	O
group	O
while	O
parents	O
participated	O
in	O
psychoeducation	O
.	O

Children	O
were	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
delayed	B-C
-	I-C
treatment	I-C
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
intravenous	B-I
immunoglobulin	I-I
therapy	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
fatigue	I-P
syndrome	I-P
.	O

METHODS	O
:	O
Forty	B-P
-	I-P
nine	I-P
patients	I-P
(	I-P
40	I-P
with	I-P
abnormal	I-P
cell	I-P
-	I-P
mediated	I-P
immunity	I-P
)	I-P
participated	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
to	O
determine	O
the	O
effectiveness	O
of	O
high	O
-	O
dose	O
intravenously	O
administered	O
immunoglobulin	B-I
G	I-I
.	O

The	O
patients	O
received	O
three	O
intravenous	O
infusions	O
of	O
a	B-C
placebo	I-C
solution	O
or	O
immunoglobulin	B-I
at	O
a	O
dose	O
of	O
2	O
g	O
/	O
kg	O
/	O
month	O
.	O

Assessment	O
of	O
the	B-O
severity	I-O
of	I-O
symptoms	I-O
and	O
associated	B-O
disability	I-O
,	O
both	O
before	O
and	O
after	O
treatment	O
,	O
was	O
completed	O
at	O
detailed	B-O
interviews	I-O
by	O
a	O
physician	O
and	O
psychiatrist	O
,	O
who	O
were	O
unaware	O
of	O
the	O
treatment	O
status	O
.	O

In	O
addition	O
,	O
any	O
change	O
in	O
physical	B-O
symptoms	I-O
and	O
functional	B-O
capacity	I-O
was	O
recorded	O
using	O
visual	B-O
analogue	I-O
scales	I-O
,	O
while	O
changes	O
in	O
psychologic	B-O
morbidity	I-O
were	O
assessed	O
using	O
patient	B-O
-	I-O
rated	I-O
indices	I-O
of	I-O
depression	I-O
.	O

Cell	B-O
-	I-O
mediated	I-O
immunity	I-O
was	O
evaluated	O
by	O
T	O
-	B-O
cell	I-O
subset	I-O
analysis	I-O
,	O
delayed	B-O
-	I-O
type	I-O
hypersensitivity	I-O
skin	I-O
testing	I-O
,	O
and	O
lymphocyte	B-O
transformation	I-O
with	I-O
phytohemagglutinin	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Theory	O
-	O
driven	O
intervention	O
improves	O
calcium	O
intake	O
,	O
osteoporosis	O
knowledge	O
,	O
and	O
self	O
-	O
efficacy	O
in	O
community	B-O
-	I-O
dwelling	I-O
older	I-O
Black	I-O
adults	I-O
.	O

METHODS	O
:	O
Randomized	O
repeated	O
measures	O
experimental	O
design	O
.	O

Churches	O
and	O
community	O
-	O
based	O
organizations	O
.	O

Men	B-P
and	I-P
women	I-P
(	I-P
n	I-P
=	I-P
110	I-P
)	I-P
50	I-P
years	I-P
old	I-P
and	I-P
older	I-P
from	I-P
3	I-P
south	I-P
Florida	I-P
counties	I-P
.	O

Participants	O
randomly	O
assigned	O
to	O
either	O
of	O
2	O
groups	O
:	O
Group	O
1	O
(	O
experimental	O
group	O
)	O
or	O
Group	O
2	O
(	O
wait	B-C
-	I-C
list	I-C
control	O
group	O
)	O
.	O

Group	O
1	O
participated	O
in	O
6	B-I
weekly	I-I
education	I-I
program	I-I
sessions	I-I
immediately	O
following	O
baseline	O
assessment	O
,	O
and	O
Group	O
2	O
started	O
the	O
program	O
following	O
Group	O
1	O
'	O
s	O
program	O
completion	O
.	O

A	O
tested	O
curriculum	O
was	O
adapted	O
to	O
meet	O
the	O
needs	O
of	O
the	O
target	O
population	O
.	O

Dietary	B-O
calcium	I-O
intake	I-O
,	O
osteoporosis	B-O
knowledge	I-O
,	O
health	B-O
beliefs	I-O
,	O
and	O
self	B-O
-	I-O
efficacy	I-O
.	O

Descriptive	O
and	O
summary	O
statistics	O
,	O
repeated	O
measures	O
analysis	O
of	O
variance	O
,	O
and	O
regression	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Pulsed	B-I
azithromycin	I-I
treatment	I-I
is	O
as	O
effective	O
and	O
safe	O
as	O
2	B-I
-	I-I
week	I-I
-	I-I
longer	I-I
daily	I-I
doxycycline	I-I
treatment	I-I
of	O
acne	O
vulgaris	O
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
noninferiority	O
study	O
.	O

METHODS	O
:	O
The	O
evaluation	O
of	O
clinical	B-O
efficacy	I-O
was	O
based	O
on	O
the	O
change	O
in	O
the	B-O
number	I-O
of	I-O
facial	I-O
inflammatory	I-O
lesions	I-O
from	O
baseline	O
to	O
the	O
end	O
of	O
treatment	O
,	O
and	O
noninferiority	B-O
was	O
defined	O
by	O
the	O
upper	O
95	O
%	O
confidence	O
limit	O
of	O
the	O
difference	O
between	O
two	O
treatments	O
being	O
less	O
than	O
9	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
intensive	B-I
insulin	I-I
therapy	I-I
on	O
the	O
somatotropic	O
axis	O
of	O
critically	B-P
ill	I-P
children	I-P
.	O

METHODS	O
:	O
This	O
was	O
a	O
preplanned	O
subanalysis	O
of	O
a	O
randomized	O
controlled	O
trial	O
on	O
IIT	O
.	O

We	O
studied	O
369	O
patients	O
who	O
stayed	O
in	O
PICU	O
for	O
at	O
least	O
3	O
d	O
(	O
study	O
1	O
)	O
and	O
126	O
patients	O
in	O
a	O
nested	O
case	O
-	O
control	O
study	O
(	O
study	O
2	O
)	O
.	O

Circulating	O
insulin	B-O
,	O
C	B-O
-	I-O
peptide	I-O
,	O
GH	B-O
,	O
IGF	B-O
-	I-O
I	I-O
,	O
bioavailable	B-O
IGF	I-O
-	I-O
I	I-O
,	O
IGF	B-O
-	I-O
binding	I-O
protein	I-O
(	I-O
IGFBP	I-O
)	I-O
-	I-O
1	I-O
,	O
IGFBP	B-O
-	I-O
3	I-O
,	O
and	O
acid	B-O
-	I-O
labile	I-O
subunit	I-O
were	O
analyzed	O
upon	O
admission	O
and	O
d	O
3	O
.	O

In	O
the	O
nested	O
case	O
-	O
control	O
study	O
,	O
the	B-O
somatotropic	I-O
axis	I-O
,	O
cortisol	B-O
,	O
and	O
glucagon	B-O
were	O
analyzed	O
before	O
and	O
after	O
hypoglycemia	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	B-I
-	I-I
dose	I-I
clonidine	I-I
administration	I-I
in	O
the	O
treatment	O
of	O
mild	O
or	O
moderate	O
essential	O
hypertension	O
:	O
results	O
from	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
(	O
Clobass	O
)	O
.	O

The	O
Clobass	O
Study	O
Group	O
.	O

METHODS	O
:	O
Eligible	O
subjects	O
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
clonidine	B-I
(	O
75	O
micrograms	O
twice	O
daily	O
)	O
or	O
a	B-C
placebo	I-C
.	O

After	O
4	O
weeks	O
,	O
'	O
responders	O
'	O
to	O
treatment	O
(	O
diastolic	B-O
blood	I-O
pressure	I-O
reduced	O
to	O
less	O
than	O
or	O
equal	O
to	O
90	O
mmHg	O
or	O
by	O
greater	O
than	O
or	O
equal	O
to	O
10	O
mmHg	O
)	O
were	O
kept	O
on	O
monotherapy	O
and	O
checked	O
at	O
4	O
-	O
weekly	O
intervals	O
for	O
another	O
3	O
months	O
.	O

Non	O
-	O
responders	O
were	O
given	O
15	O
mg	O
chlorthalidone	O
and	O
were	O
also	O
checked	O
for	O
a	O
further	O
3	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Single	B-I
-	I-I
agent	I-I
irinotecan	I-I
or	O
FOLFIRI	B-I
as	O
second	O
-	O
line	O
chemotherapy	O
for	O
advanced	O
colorectal	O
cancer	O
;	O
results	O
of	O
a	O
randomised	O
phase	O
II	O
study	O
(	O
DaVINCI	O
)	O
and	O
meta	O
-	O
analysis	O
[	O
corrected	O
]	O
.	O

METHODS	O
:	O
In	O
DaVINCI	O
,	O
a	O
randomised	O
phase	O
II	O
trial	O
,	O
patients	B-P
with	I-P
advanced	I-P
colorectal	I-P
cancer	I-P
were	O
randomly	O
allocated	O
to	O
:	O
Combination	B-I
therapy	I-I
(	I-I
FOLFIRI	I-I
)	I-I
,	O
irinotecan	B-I
(	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
over	O
90	O
min	O
,	O
day	O
1	O
)	O
,	O
5	B-I
-	I-I
fluorouracil	I-I
(	O
400mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
bolus	O
and	O
2400	O
mg	O
/	O
m	O
(	O
2	O
)	O
by	O
46	O
-	O
hour	O
infusion	O
from	O
day	O
1	O
)	O
and	O
folinic	B-I
acid	I-I
(	O
20mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
bolus	O
,	O
day	O
1	O
)	O
,	O
2	O
-	O
weekly	O
;	O
or	O
Single	B-I
-	I-I
agent	I-I
,	I-I
irinotecan	I-I
(	O
350	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
over	O
90	O
min	O
)	O
,	O
3	O
-	O
weekly	O
.	O

Toxicity	B-O
was	O
evaluated	O
every	O
treatment	O
cycle	O
;	O
QOL	B-O
and	O
response	B-O
6	O
-	O
weekly	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

The	O
trial	O
,	O
amended	O
from	O
a	O
larger	O
factorial	O
design	O
,	O
was	O
terminated	O
early	O
due	O
to	O
slow	O
recruitment	O
.	O

Results	O
were	O
also	O
combined	O
with	O
other	O
second	O
-	O
line	O
irinotecan	O
trials	O
.	O

-DOCSTART-	O

Title	O
:	O
Alternating	B-I
chemotherapy	I-I
in	O
small	O
cell	O
lung	O
cancer	O
.	O

METHODS	O
:	O
Recently	O
,	O
most	O
trials	O
were	O
designed	O
as	O
2	O
-	O
arm	O
approaches	O
with	O
a	O
comparison	O
of	O
continuous	O
standard	O
therapy	O
based	O
on	O
the	O
CAV	O
-	O
or	O
CMC	O
-	O
protocol	O
with	O
an	O
alternating	O
schedule	O
often	O
consisting	O
of	O
the	O
CAV	O
-	O
or	O
CMC	O
-	O
derived	O
combinations	O
and	O
a	O
second	O
regimen	O
including	O
cisplatinum	O
and	O
/	O
or	O
etoposide	O
.	O

METHODS	O
:	O
To	O
ameliorate	O
this	O
weakness	O
,	O
3	O
studies	O
were	O
designed	O
as	O
3	O
-	O
arms	O
approaches	O
using	O
both	O
alternating	O
protocols	O
as	O
continuous	O
control	O
arms	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
pilot	O
randomized	O
controlled	O
trial	O
of	O
DIR	B-I
/	I-I
Floortime	I-I
parent	I-I
training	I-I
intervention	I-I
for	O
pre	B-P
-	I-P
school	I-P
children	I-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
.	O

METHODS	O
:	O
Measures	O
of	O
functional	B-O
emotional	I-O
development	I-O
and	O
symptom	B-O
severity	I-O
were	O
taken	O
.	O

-DOCSTART-	O

Title	O
:	O
Validity	O
and	O
reliability	O
assessment	O
of	O
the	B-I
Siriraj	I-I
Asthma	I-I
Control	I-I
Questionnaire	I-I
.	O

METHODS	O
:	O
The	O
data	O
of	O
the	B-I
questionnaire	I-I
responses	O
and	O
spirometric	B-I
results	I-I
from	O
20	B-P
randomized	I-P
asthmatic	I-P
patients	I-P
in	I-P
the	I-P
clinic	I-P
including	I-P
the	I-P
record	I-P
of	I-P
3	I-P
visits	I-P
for	I-P
each	I-P
subject	I-P
.	O

The	B-O
validation	I-O
was	O
performed	O
by	O
Kruskal	O
-	O
Wallis	O
test	O
comparing	O
the	B-O
scores	I-O
with	I-O
the	I-O
level	I-O
of	I-O
asthma	I-O
control	O
determined	O
by	O
physicians	O
according	O
to	O
GINA	O
guideline	O
.	O

Internal	B-O
consistency	I-O
reliability	I-O
was	O
analyzed	O
by	O
Cronbach	O
'	O
s	O
alpha	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
shearing	O
on	O
water	O
turnover	O
and	O
thermobiological	O
variables	O
in	O
German	B-P
Blackhead	I-P
mutton	I-P
sheep	I-P
.	O

METHODS	O
:	O
Fourteen	B-P
nonlactating	I-P
German	I-P
Blackhead	I-P
mutton	I-P
ewes	I-P
were	O
randomly	O
allocated	O
into	O
2	O
groups	O
:	O
a	O
control	O
group	O
(	O
n	O
=	O
7	O
)	O
that	O
was	O
already	B-C
shorn	I-C
,	O
and	O
a	O
treatment	O
group	O
(	O
n	O
=	O
7	O
)	O
that	O
was	O
left	B-I
unshorn	I-I
(	O
wool	O
length	O
:	O
10	O
.	O
6	O
	O
1	O
.	O
2	O
cm	O
)	O
.	O

Individual	B-O
feed	I-O
and	O
water	B-O
intakes	I-O
were	O
recorded	O
throughout	O
the	O
experiment	O
(	O
d	O
1	O
to	O
71	O
)	O
.	O

Two	O
weeks	O
after	O
measurements	O
commenced	O
(	O
d	O
15	O
)	O
,	O
treatment	O
sheep	O
were	O
shorn	O
.	O

Water	B-O
intake	I-O
was	O
estimated	O
twice	O
for	O
2	O
consecutive	O
weeks	O
by	O
using	O
deuterium	B-O
dilution	I-O
techniques	I-O
(	O
d	O
1	O
to	O
15	O
and	O
d	O
57	O
to	O
71	O
)	O
.	O

Ambient	B-O
temperature	I-O
(	O
T	O
(	O
a	O
)	O
)	O
,	O
relative	B-O
humidity	I-O
,	O
and	O
respiratory	B-O
rate	I-O
were	O
measured	O
daily	O
,	O
whereas	O
BW	B-O
,	O
rectal	B-O
and	O
animal	B-O
surface	I-O
temperatures	I-O
(	O
using	O
infrared	B-O
thermography	I-O
)	O
,	O
and	O
wool	B-O
length	I-O
were	O
measured	O
weekly	O
.	O

-DOCSTART-	O

Title	O
:	O
Using	O
the	B-I
transporters	I-I
DVD	I-I
as	O
a	O
learning	O
tool	O
for	O
children	B-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorders	I-P
(	I-P
ASD	I-P
)	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
gravity	O
on	O
robot	B-I
-	I-I
assisted	I-I
motor	I-I
training	I-I
after	O
chronic	O
stroke	O
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
trial	O
,	O
single	O
-	O
blinded	O
,	O
with	O
12	O
-	O
week	O
follow	O
-	O
up	O
.	O

Research	O
setting	O
in	O
a	O
large	O
medical	O
center	O
.	O

Adults	B-P
(	I-P
N=62	I-P
)	I-P
with	I-P
chronic	I-P
,	I-P
stroke	I-P
-	I-P
related	I-P
arm	I-P
weakness	I-P
stratified	I-P
by	I-P
impairment	I-P
severity	I-P
using	I-P
baseline	I-P
UE	I-P
motor	I-P
assessments	I-P
.	O

Sixty	B-I
minutes	I-I
,	I-I
3	I-I
times	I-I
a	I-I
week	I-I
for	I-I
6	I-I
weeks	I-I
of	I-I
robot	I-I
-	I-I
assisted	I-I
planar	I-I
reaching	I-I
(	I-I
gravity	I-I
compensated	I-I
)	I-I
,	O
combined	O
planar	B-I
with	I-I
vertical	I-I
robot	I-I
-	I-I
assisted	I-I
reaching	I-I
,	O
or	O
intensive	B-C
conventional	I-C
arm	I-C
exercise	I-C
program	I-C
.	O

UE	B-O
Fugl	I-O
-	I-O
Meyer	I-O
Assessment	I-O
(	I-O
FMA	I-O
)	I-O
mean	O
change	O
from	O
baseline	O
to	O
final	O
training	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
ozone	B-I
application	I-I
on	O
the	O
resin	O
-	O
dentin	O
microtensile	O
bond	O
strength	O
.	O

METHODS	O
:	O
Forty	B-P
human	I-P
third	I-P
molars	I-P
were	O
divided	O
into	O
four	O
groups	O
:	O
Group	O
1	O
,	O
not	B-C
treated	I-C
with	I-C
ozone	I-C
;	O
Group	O
2	O
,	O
ozone	B-I
application	I-I
followed	O
by	O
acid	B-I
etching	I-I
;	O
Group	O
3	O
,	O
acid	B-I
etching	I-I
followed	O
by	O
ozone	B-I
application	I-I
;	O
and	O
Group	O
4	O
,	O
ozone	B-I
and	I-I
application	I-I
of	I-I
sodium	I-I
ascorbate	I-I
.	O

Bonded	B-O
beams	I-O
(	O
1	O
.	O
0	O
mm	O
(	O
2	O
)	O
)	O
were	O
tested	O
under	O
tension	B-O
(	O
0	O
.	O
5	O
mm	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	B-O
?TBS	I-O
values	I-O
were	O
analyzed	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
and	O
the	B-O
Tukey	I-O
test	I-O
(	O
p=0	O
.	O
05	O
)	O
.	O

All	O
beams	O
that	O
fractured	O
were	O
analyzed	O
under	O
stereomicroscopy	B-O
(	O
40	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Symptomatic	O
and	O
functional	O
improvement	O
in	O
employed	B-P
depressed	I-P
patients	I-P
:	O
a	O
double	O
-	O
blind	O
clinical	O
trial	O
of	O
desvenlafaxine	B-I
versus	O
placebo	B-C
.	O

METHODS	O
:	O
Gainfully	B-P
employed	I-P
(	I-P
?20	I-P
h	I-P
/	I-P
wk	I-P
)	I-P
male	I-P
and	I-P
female	I-P
outpatients	I-P
with	I-P
MDD	I-P
were	O
randomly	O
assigned	O
(	O
2	O
:	O
1	O
ratio	O
)	O
to	O
12	O
weeks	O
of	O
double	O
-	O
blind	O
treatment	O
with	O
desvenlafaxine	B-I
50	O
mg	O
/	O
d	O
or	O
placebo	B-C
.	O

Analysis	O
of	O
covariance	O
was	O
used	O
to	O
compare	O
differences	O
in	O
week	O
12	O
adjusted	O
mean	O
changes	O
from	O
baseline	O
on	O
the	B-O
17	I-O
-	I-O
item	I-O
Hamilton	I-O
Depression	I-O
Rating	I-O
Scale	I-O
(	I-O
HAM	I-O
-	I-O
D??	I-O
)	I-O
(	O
primary	O
outcome	O
)	O
and	O
Sheehan	B-O
Disability	I-O
Scale	I-O
(	I-O
SDS	I-O
)	I-O
(	O
key	O
secondary	O
outcome	O
)	O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
.	O

A	O
predefined	O
,	O
modified	B-O
ITT	I-O
population	I-O
(	O
ie	O
,	O
those	O
in	O
the	O
ITT	O
population	O
with	O
baseline	O
HAM	O
-	O
D??	O
?20	O
)	O
was	O
also	O
analyzed	O
.	O

Tolerability	B-O
was	O
assessed	O
by	O
recording	O
adverse	O
events	O
and	O
change	O
on	O
the	B-O
Arizona	I-O
Sexual	I-O
Experience	I-O
Scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Sublingually	O
administered	O
captopril	B-I
versus	O
nifedipine	B-I
in	O
hypertension	O
emergencies	O
]	O
.	O

METHODS	O
:	O
During	O
hypertensive	O
crises	O
(	O
systolic	O
blood	O
pressure	O
exceeding	O
200	O
mmHg	O
and	O
diastolic	O
blood	O
pressure	O
exceeding	O
115	O
mmHg	O
)	O
forty	B-P
hypertensive	I-P
patients	I-P
received	O
either	O
25	B-I
mg	I-I
of	I-I
SLC	I-I
or	O
10	B-I
mg	I-I
of	I-I
SLN	I-I
in	O
a	O
randomized	O
single	O
blind	O
fashion	O
.	O

Blood	B-O
pressure	I-O
and	O
heart	B-O
rate	I-O
were	O
then	O
controlled	O
after	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
120	O
min	O
.	O

and	O
,	O
in	O
18	O
cases	O
,	O
up	O
to	O
the	O
8th	O
hour	O
from	O
the	O
administration	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
an	B-I
induction	I-I
period	I-I
of	I-I
pegylated	I-I
interferon	I-I
-	I-I
?2a	I-I
and	O
ribavirin	B-I
on	O
early	O
virological	O
response	O
in	O
HIV	B-P
-	I-P
HCV	I-P
-	I-P
coinfected	I-P
patients	I-P
:	O
results	O
from	O
the	O
CORAL	O
-	O
2	O
study	O
.	O

METHODS	O
:	O
HIV	B-P
and	I-P
HCV	I-P
genotype	I-P
1	I-P
-	I-P
and	I-P
4	I-P
-	I-P
coinfected	I-P
subjects	I-P
were	O
randomized	O
to	O
receive	O
pegylated	B-I
interferon	I-I
-	I-I
?2a	I-I
270	O
?g	O
/	O
week	O
plus	O
ribavirin	B-I
1	O
,	O
600	O
mg	O
daily	O
and	O
epoetin	B-I
-	I-I
?	I-I
for	O
4	O
weeks	O
,	O
followed	O
by	O
pegylated	B-I
interferon	I-I
-	I-I
?2a	I-I
at	O
standard	O
dosages	O
plus	O
weight	B-I
-	I-I
based	I-I
ribavirin	I-I
(	I-I
WBR	I-I
)	I-I
dosage	O
for	O
8	O
weeks	O
(	O
induction	O
arm	O
[	O
IA	O
]	O
)	O
,	O
or	O
pegylated	B-I
interferon	I-I
-	I-I
?2a	I-I
plus	O
WBR	B-I
for	O
12	O
weeks	O
(	O
standard	O
therapy	O
arm	O
[	O
SA	O
]	O
)	O
.	O

HCV	B-O
RNA	I-O
was	O
determined	O
at	O
weeks	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
8	O
and	O
12	O
.	O

Ribavirin	B-O
plasma	I-O
trough	I-O
concentrations	I-O
were	O
determined	O
at	O
weeks	O
4	O
(	O
RBV	O
-	O
C	O
(	O
4	O
)	O
)	O
and	O
12	O
(	O
RBV	O
-	O
C	O
(	O
12	O
)	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Social	B-I
skills	I-I
training	I-I
for	O
young	B-P
adults	I-P
with	I-P
high	I-P
-	I-P
functioning	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
randomized	O
controlled	O
pilot	O
study	O
.	O

METHODS	O
:	O
Using	O
a	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
design	O
,	O
the	O
current	O
study	O
tested	O
the	O
effectiveness	O
of	O
an	B-I
evidence	I-I
-	I-I
based	I-I
,	I-I
caregiver	I-I
-	I-I
assisted	I-I
social	I-I
skills	I-I
intervention	I-I
known	O
as	O
PEERS	B-I
for	O
Young	B-P
Adults	I-P
with	I-P
high	I-P
-	I-P
functioning	I-P
young	I-P
adults	I-P
with	I-P
ASD	I-P
(	I-P
ages	I-P
18	I-P
-	I-P
23	I-P
)	I-P
using	O
self	O
-	O
and	O
caregiver	O
-	O
report	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
The	O
equipotency	O
of	O
ropivacaine	B-I
,	O
bupivacaine	B-I
and	O
etidocaine	B-I
]	O
.	O

METHODS	O
.	O

METHODS	O
:	O
In	O
a	O
double	O
blind	O
randomized	O
study	O
,	O
epidural	B-I
anesthesia	I-I
was	O
carried	O
out	O
with	O
20	B-I
ml	I-I
bupivacaine	I-I
0	O
.	O
75	O
%	O
(	O
n	O
=	O
24	O
)	O
and	O
ropivacaine	B-I
1	O
%	O
(	O
n	O
=	O
21	O
)	O
.	O

Following	O
this	O
study	O
epidural	B-I
anesthesia	I-I
was	O
carried	O
out	O
with	O
20	B-I
ml	I-I
etidocaine	I-I
1	O
%	O
(	O
n	O
=	O
20	O
)	O
in	O
an	O
open	O
study	O
.	O

Patients	B-P
with	I-P
ASA	I-P
I	I-P
or	I-P
II	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

All	O
patients	O
were	O
scheduled	O
for	O
varicose	O
vein	O
stripping	O
.	O

Male	B-P
and	I-P
female	I-P
patients	I-P
aged	I-P
18	I-P
-	I-P
70	I-P
years	I-P
and	I-P
weighing	I-P
50	I-P
-	I-P
100	I-P
kg	I-P
were	O
included	O
in	O
the	O
study	O
.	O

Patients	O
were	O
all	O
placed	O
in	O
a	O
sitting	O
position	O
,	O
after	O
which	O
the	O
epidural	O
space	O
was	O
identified	O
by	O
the	O
"	O
loss	O
of	O
resistance	O
"	O
technique	O
and	O
a	O
midline	O
approach	O
,	O
at	O
the	O
L	O
-	O
3	O
/	O
4	O
interspace	O
.	O

Injections	O
of	O
3	O
ml	O
of	O
the	O
local	O
anesthetic	O
were	O
given	O
,	O
followed	O
by	O
the	O
remainder	O
of	O
the	O
local	O
anesthetic	O
at	O
10	O
ml	O
/	O
min	O
1	O
min	O
later	O
.	O

METHODS	O
:	O
The	O
two	O
-	O
segment	O
regression	O
time	O
was	O
199	O
+	O
/	O
-	O
80	O
min	O
for	O
bupivacaine	O
,	O
201	O
+	O
/	O
-	O
52	O
min	O
for	O
ropivacaine	O
,	O
and	O
174	O
+	O
/	O
-	O
81	O
min	O
for	O
etidocaine	O
.	O

The	O
total	O
duration	O
of	O
sensory	O
block	O
was	O
340	O
+	O
/	O
-	O
103	O
min	O
for	O
bupivacaine	O
,	O
428	O
+	O
/	O
-	O
65	O
min	O
for	O
ropivacaine	O
and	O
223	O
+	O
/	O
-	O
62	O
min	O
for	O
etidocaine	O
,	O
respectively	O
.	O

In	O
the	O
ropivacaine	O
and	O
bupivacaine	O
groups	O
sensory	O
anesthesia	O
was	O
considered	O
adequate	O
for	O
surgery	O
in	O
all	O
cases	O
but	O
one	O
in	O
each	O
group	O
;	O
in	O
the	O
etidocaine	O
group	O
,	O
however	O
60	O
%	O
of	O
the	O
patients	O
showed	O
inadequate	O
analgesia	O
and	O
all	O
these	O
patients	O
(	O
12	O
/	O
20	O
)	O
required	O
additional	O
analgesics	O
.	O

Bupivacaine	O
achieved	O
an	O
average	O
of	O
motor	O
block	O
2	O
.	O
1	O
,	O
ropivacaine	O
2	O
.	O
3	O
,	O
and	O
etidocaine	O
2	O
.	O
4	O
.	O

CONCLUSION	O
.	O

-DOCSTART-	O

Title	O
:	O
Polymorphisms	B-I
of	I-I
ADORA2A	I-I
modulate	O
psychomotor	O
vigilance	O
and	O
the	O
effects	O
of	O
caffeine	B-I
on	O
neurobehavioural	O
performance	O
and	O
sleep	O
EEG	O
after	O
sleep	O
deprivation	O
.	O

METHODS	O
:	O
A	O
haplotype	O
analysis	O
of	O
eight	B-I
single	I-I
-	I-I
nucleotide	I-I
polymorphisms	I-I
of	I-I
ADORA2A	I-I
was	O
performed	O
in	O
82	B-P
volunteers	I-P
.	O

In	O
45	O
young	O
men	O
carrying	O
five	O
different	O
allele	O
combinations	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
prolonged	B-I
waking	I-I
and	O
2	B-I
	I-I
200	I-I
mg	I-I
caffeine	I-I
or	O
2	B-I
	I-I
100	I-I
mg	I-I
modafinil	I-I
on	O
psychomotor	B-O
vigilance	I-O
,	O
sleepiness	B-O
,	O
and	O
the	B-O
waking	I-O
and	O
sleep	B-O
EEG	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Methodologic	O
comparison	O
of	O
the	O
polyfrequency	O
oscillation	O
method	O
,	O
transcutaneous	O
oxygen	O
pressure	O
measurement	O
and	O
body	O
plethysmography	O
in	O
bronchial	O
provocation	O
with	O
methacholine	B-I
]	O
.	O

METHODS	O
:	O
A	B-O
bronchial	I-O
provocation	I-O
challenge	I-O
test	I-O
was	O
conducted	O
with	O
30	B-P
subjects	I-P
using	O
metacholin	B-I
.	O

In	O
randomised	O
sequence	O
lung	B-O
function	I-O
analysis	I-O
tests	I-O
were	O
carried	O
out	O
with	O
the	B-O
bodyplethysmograph	I-O
(	O
Raw	O
,	O
FEV1	O
)	O
and	O
the	B-O
polyfrequent	I-O
oscillation	I-O
method	I-O
(	O
resistance	B-O
,	O
reactance	B-O
between	O
2	O
and	O
52	O
Hz	O
)	O
,	O
whereas	O
the	B-O
transcutaneous	I-O
oxygen	I-O
pressure	I-O
(	I-O
tc	I-O
-	I-O
PO2	I-O
)	I-O
was	O
measured	O
continuously	O
.	O

Correlations	O
between	O
the	O
various	O
parameters	O
,	O
the	O
change	O
of	O
the	B-O
values	I-O
at	I-O
PD60	I-O
sGaw	I-O
in	O
relation	O
to	O
the	O
initial	O
values	O
,	O
the	B-O
interindividual	I-O
variability	I-O
and	O
the	B-O
reactivity	I-O
were	O
determined	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Comparative	O
effects	O
of	O
nebivolol	B-I
and	O
valsartan	B-I
on	O
atrial	O
electromechanical	O
coupling	O
in	O
newly	B-P
diagnosed	I-P
stage	I-P
1	I-P
hypertensive	I-P
patients	I-P
]	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
60	B-P
newly	I-P
diagnosed	I-P
stage	I-P
1	I-P
hypertensive	I-P
patients	I-P
with	I-P
no	I-P
other	I-P
systemic	I-P
disease	I-P
.	O

The	O
patients	O
were	O
randomized	O
to	O
receive	O
nebivolol	B-I
5	O
mg	O
(	O
30	O
patients	O
;	O
21	O
women	O
,	O
9	O
men	O
;	O
mean	O
age	O
48	O
.	O
4	O
	O
11	O
.	O
4	O
years	O
)	O
and	O
valsartan	B-I
160	O
mg	O
(	O
30	O
patients	O
;	O
21	O
women	O
,	O
9	O
men	O
;	O
mean	O
age	O
49	O
.	O
8	O
	O
11	O
.	O
3	O
years	O
)	O
.	O

All	O
the	O
patients	O
underwent	O
tissue	B-O
Doppler	I-O
echocardiographic	I-O
examination	I-O
before	O
and	O
three	O
months	O
after	O
treatment	O
to	O
compare	O
the	O
effects	O
of	O
the	O
two	O
drugs	O
on	O
atrial	O
electromechanical	O
coupling	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
body	B-I
orientation	I-I
on	O
maximum	O
voluntary	O
arm	O
torques	O
.	O

METHODS	O
:	O
Maximum	B-O
isometric	I-O
single	I-O
-	I-O
joint	I-O
and	O
multi	B-O
-	I-O
joint	I-O
arm	I-O
strength	I-O
was	O
observed	O
in	O
two	B-I
body	I-I
orientations	I-I
(	O
sitting	B-I
and	O
supine	B-I
)	O
while	O
maintaining	O
identical	O
head	O
/	O
neck	O
/	O
trunk	O
/	O
extremity	O
joint	O
configurations	O
in	O
order	O
to	O
identify	O
bulbospinal	O
contributions	O
to	O
maximum	O
joint	O
torque	O
generation	O
in	O
11	O
individuals	O
with	O
stroke	O
and	O
10	O
individuals	O
without	O
stroke	O
.	O

-DOCSTART-	O

Title	O
:	O
Arthroscopic	B-I
rotator	I-I
cuff	I-I
repair	I-I
with	I-I
and	O
without	B-I
acromioplasty	I-I
in	O
the	O
treatment	O
of	O
full	O
-	O
thickness	O
rotator	O
cuff	O
tears	O
:	O
a	O
multicenter	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Eighty	B-P
-	I-P
six	I-P
patients	I-P
consented	O
and	O
were	O
randomly	O
assigned	O
intraoperatively	O
to	O
one	O
of	O
two	O
study	O
groups	O
,	O
and	O
sixty	O
-	O
eight	O
of	O
them	O
completed	O
the	O
study	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
Western	I-O
Ontario	I-O
Rotator	I-O
Cuff	I-O
(	I-O
WORC	I-O
)	I-O
index	I-O
.	O

Secondary	O
outcome	O
measures	O
included	O
the	B-O
American	I-O
Shoulder	I-O
and	I-O
Elbow	I-O
Surgeons	I-O
(	I-O
ASES	I-O
)	I-O
shoulder	I-O
assessment	I-O
form	I-O
and	O
a	O
count	O
of	O
revisions	O
required	O
in	O
each	O
group	O
.	O

Outcome	O
measures	O
were	O
completed	O
preoperatively	O
and	O
at	O
three	O
,	O
six	O
,	O
twelve	O
,	O
eighteen	O
,	O
and	O
twenty	O
-	O
four	O
months	O
after	O
surgery	O
.	O

-DOCSTART-	O

Title	O
:	O
Atrial	B-I
fibrillation	I-I
catheter	I-I
ablation	I-I
versus	O
surgical	B-I
ablation	I-I
treatment	I-I
(	I-I
FAST	I-I
)	I-I
:	O
a	O
2	O
-	O
center	O
randomized	O
clinical	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
Development	O
of	O
an	B-I
adaptive	I-I
low	I-I
-	I-I
pass	I-I
filtered	I-I
speech	I-I
test	I-I
for	O
the	O
identification	O
of	O
auditory	O
processing	O
disorders	O
.	O

METHODS	O
:	O
In	O
this	O
preliminary	O
study	O
,	O
33	B-P
adults	I-P
and	I-P
30	I-P
children	I-P
(	I-P
aged	I-P
8	I-P
-	I-P
11	I-P
years	I-P
)	I-P
with	I-P
no	I-P
known	I-P
history	I-P
of	I-P
listening	I-P
difficulties	I-P
were	O
tested	O
.	O

The	B-I
University	I-I
of	I-I
Canterbury	I-I
Adaptive	I-I
Speech	I-I
Test	I-I
(	I-I
UCAST	I-I
)	I-I
platform	I-I
was	O
used	O
to	O
administer	O
a	B-I
four	I-I
-	I-I
alternative	I-I
forced	I-I
-	I-I
choice	I-I
adaptive	I-I
test	I-I
that	O
altered	O
a	O
low	O
-	O
pass	O
filter	O
(	O
LPF	O
)	O
to	O
track	O
the	B-O
corner	I-O
frequency	I-O
at	O
which	O
participants	O
correctly	O
identified	O
a	B-O
certain	I-O
percentage	I-O
of	I-O
the	I-O
word	I-O
stimuli	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Tinzaparin	B-I
versus	O
dalteparin	B-I
for	O
periprocedure	O
prophylaxis	O
of	O
thromboembolic	O
events	O
in	O
hemodialysis	B-P
patients	I-P
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Open	O
-	O
label	O
randomized	O
controlled	O
trial	O
.	O

HD	B-P
patients	I-P
undergoing	I-P
periprocedure	I-P
bridging	I-P
anticoagulation	I-P
.	O

After	O
warfarin	O
therapy	O
was	O
discontinued	O
,	O
participants	O
were	O
randomly	O
assigned	O
to	O
either	O
3	B-I
daily	I-I
doses	I-I
of	I-I
tinzaparin	I-I
(	O
175	O
IU	O
/	O
kg	O
)	O
or	O
dalteparin	B-I
(	O
200	O
IU	O
/	O
kg	O
)	O
,	O
with	O
2	O
intervening	O
HD	O
treatments	O
between	O
the	O
first	O
dose	O
of	O
study	O
drug	O
and	O
their	O
procedure	O
.	O

-DOCSTART-	O

Title	O
:	O
Teacher	B-I
-	I-I
implemented	I-I
joint	I-I
attention	I-I
intervention	I-I
:	O
pilot	O
randomized	O
controlled	O
study	O
for	O
preschoolers	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
Sixteen	B-P
dyads	I-P
(	I-P
preschoolers	I-P
with	I-P
ASD	I-P
and	I-P
the	I-P
public	I-P
school	I-P
teachers	I-P
who	I-P
worked	I-P
in	I-P
the	I-P
child	I-P
'	I-P
s	I-P
classroom	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
the	B-I
6	I-I
-	I-I
week	I-I
JASP	I-I
/	I-I
ER	I-I
intervention	I-I
or	O
a	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
skin	B-I
-	I-I
to	I-I
-	I-I
skin	I-I
contact	I-I
on	O
autonomic	O
pain	O
responses	O
in	O
preterm	B-P
infants	I-P
.	O

The	O
purpose	O
of	O
this	O
randomized	O
crossover	O
trial	O
was	O
to	O
determine	O
the	O
effects	O
on	O
autonomic	O
responses	O
in	O
preterm	O
infants	O
of	O
longer	O
Kangaroo	O
Care	O
(	O
30	O
minutes	O
,	O
KC30	O
)	O
and	O
shorter	O
KC	O
(	O
15	O
minutes	O
,	O
KC15	O
)	O
before	O
and	O
throughout	O
heel	O
stick	O
compared	O
with	O
incubator	O
care	O
(	O
IC	O
)	O
.	O

Beat	O
-	O
to	O
-	O
beat	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
spectral	O
power	O
analysis	O
of	O
heart	O
rate	O
variability	O
,	O
low	O
frequency	O
power	O
(	O
LF	O
)	O
,	O
high	O
frequency	O
power	O
(	O
HF	O
)	O
,	O
and	O
LF	O
/	O
HF	O
ratio	O
were	O
measured	O
in	O
26	O
infants	O
.	O

HR	O
changes	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
were	O
significantly	O
less	O
in	O
KC30	O
and	O
KC15	O
than	O
in	O
IC	O
,	O
and	O
more	O
infants	O
had	O
HR	O
decrease	O
in	O
IC	O
than	O
in	O
2	O
KC	O
conditions	O
.	O

In	O
IC	O
,	O
LF	O
and	O
HF	O
significantly	O
increased	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
and	O
dropped	O
from	O
Heel	O
Stick	O
to	O
Recovery	O
;	O
in	O
2	O
KC	O
conditions	O
,	O
no	O
changes	O
across	O
study	O
phases	O
were	O
found	O
.	O

During	O
Heel	O
Stick	O
,	O
LF	O
and	O
HF	O
were	O
significantly	O
higher	O
in	O
IC	O
than	O
in	O
KC30	O
.	O

In	O
all	O
3	O
conditions	O
,	O
LF	O
/	O
HF	O
ratio	O
decreased	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
and	O
increased	O
to	O
Recovery	O
;	O
no	O
differences	O
were	O
found	O
between	O
IC	O
and	O
two	O
KC	O
conditions	O
.	O

Both	O
longer	O
and	O
shorter	O
KC	O
before	O
and	O
throughout	O
heel	O
stick	O
can	O
stabilize	O
HR	O
response	O
in	O
preterm	O
infants	O
,	O
and	O
longer	O
KC	O
significantly	O
affected	O
infants	O
'	O
sympathetic	O
and	O
parasympathetic	O
responses	O
during	O
heel	O
stick	O
compared	O
with	O
incubator	O
care	O
.	O

-DOCSTART-	O

Title	O
:	O
Plerixafor	B-I
plus	I-I
granulocyte	I-I
colony	I-I
-	I-I
stimulating	I-I
factor	I-I
versus	O
placebo	B-C
plus	I-C
granulocyte	I-C
colony	I-C
-	I-C
stimulating	I-C
factor	I-C
for	O
mobilization	O
of	O
CD34	O
(	O
+	O
)	O
hematopoietic	O
stem	O
cells	O
in	O
patients	B-P
with	I-P
multiple	I-P
myeloma	I-P
and	I-P
low	I-P
peripheral	I-P
blood	I-P
CD34	I-P
(	I-P
+	I-P
)	I-P
cell	I-P
count	I-P
:	O
results	O
of	O
a	O
subset	O
analysis	O
of	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
post	O
hoc	O
analysis	O
,	O
we	O
evaluated	O
the	O
mobilization	O
efficacy	O
of	O
plerixafor	B-I
plus	I-I
granulocyte	I-I
colony	I-I
-	I-I
stimulating	I-I
factor	I-I
(	I-I
G	I-I
-	I-I
CSF	I-I
)	I-I
versus	O
placebo	B-C
plus	I-C
G	I-C
-	I-C
CSF	I-C
in	O
patients	B-P
with	I-P
multiple	I-P
myeloma	I-P
,	I-P
stratified	I-P
by	I-P
preapheresis	I-P
PB	I-P
CD34	I-P
(	I-P
+	I-P
)	I-P
cell	I-P
count	I-P
:	I-P
<	I-P
10	I-P
,	I-P
<	I-P
15	I-P
,	I-P
<	I-P
20	I-P
,	I-P
and	I-P
?20	I-P
cells	I-P
/	I-P
?L	I-P
.	O

Regardless	O
of	O
the	B-O
PB	I-O
CD34	I-O
(	I-O
+	I-O
)	I-O
cell	I-O
count	I-O
,	O
the	B-O
total	I-O
yield	I-O
of	I-O
CD34	I-O
(	I-O
+	I-O
)	I-O
cells	I-O
from	I-O
apheresis	I-O
was	O
significantly	O
higher	O
in	O
the	B-I
plerixafor	I-I
group	O
than	O
in	O
the	B-C
placebo	I-C
group	O
,	O
and	O
significantly	O
more	O
patients	O
in	O
the	B-I
plerixafor	I-I
group	O
collected	O
the	O
minimum	O
(	O
?2	O
	O
10	O
(	O
6	O
)	O
cells	O
/	O
kg	O
)	O
and	O
optimum	O
(	O
?6	O
	O
10	O
(	O
6	O
)	O
cells	O
/	O
kg	O
)	O
stem	O
cell	O
yields	O
on	O
each	O
day	O
of	O
apheresis	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
acute	O
effects	O
of	O
fluid	B-I
intake	I-I
on	O
urine	O
specific	O
gravity	O
and	O
fluid	O
retention	O
in	O
a	O
mildly	O
dehydrated	O
state	O
.	O

METHODS	O
:	O
Ten	B-P
recreational	I-P
athletes	I-P
(	I-P
6	I-P
women	I-P
,	I-P
4	I-P
men	I-P
;	I-P
71	I-P
.	I-P
9	I-P
	I-P
4	I-P
.	I-P
6	I-P
kg	I-P
,	I-P
25	I-P
.	I-P
2	I-P
	I-P
0	I-P
.	I-P
9	I-P
years	I-P
)	I-P
participated	O
in	O
the	O
studies	O
to	O
examine	O
(	O
a	O
)	O
the	B-O
day	I-O
-	I-O
to	I-O
-	I-O
day	I-O
variability	I-O
of	I-O
morning	I-O
urine	I-O
specific	I-O
gravity	I-O
(	I-O
USG	I-O
)	I-O
,	O
(	O
b	O
)	O
the	B-O
effects	I-O
of	I-O
consuming	I-O
600	I-O
ml	I-O
of	I-O
water	I-O
on	I-O
the	I-O
hydration	I-O
status	I-O
of	I-O
HYD	I-O
and	I-O
HYPO	I-O
(	I-O
USG	I-O
>	I-O
1	I-O
.	I-O
020	I-O
)	I-O
subjects	I-O
,	O
and	O
(	O
c	O
)	O
the	B-O
effects	I-O
of	I-O
consuming	I-O
water	I-O
(	I-O
W	I-O
)	I-O
,	O
salt	B-O
-	I-O
water	I-O
(	I-O
SW	I-O
,	I-O
40	I-O
mM	I-O
Na	I-O
)	I-O
,	O
a	B-O
carbohydrate	I-O
-	I-O
electrolyte	I-O
solution	I-O
with	I-O
3	I-O
%	I-O
or	I-O
light	I-O
carbohydrate	I-O
(	I-O
CES	I-O
-	I-O
L	I-O
,	I-O
20	I-O
mM	I-O
Na	I-O
)	I-O
or	O
a	B-O
CES	I-O
with	I-O
6	I-O
%	I-O
carbohydrate	I-O
(	I-O
CES	I-O
,	I-O
20	I-O
mM	I-O

Na	I-O
)	I-O
on	I-O
the	I-O
hydration	I-O
status	I-O
of	O
HYPO	O
subjects	O
.	O

The	B-O
hydration	I-O
status	I-O
was	O
assessed	O
with	O
USG	B-O
and	O
body	B-O
mass	I-O
measures	I-O
and	O
urine	B-O
volume	I-O
collections	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Pentraxin	B-I
-	I-I
3	I-I
in	O
chronic	O
heart	O
failure	O
:	O
the	O
CORONA	O
and	O
GISSI	O
-	O
HF	O
trials	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
impact	O
of	O
patient	B-I
and	O
physician	B-I
computer	I-I
mediated	I-I
communication	I-I
skill	I-I
training	I-I
on	O
reported	O
communication	O
and	O
patient	O
satisfaction	O
.	O

METHODS	O
:	O
Separate	B-I
patient	I-I
and	I-I
clinician	I-I
web	I-I
-	I-I
tools	I-I
comprised	I-I
of	I-I
over	I-I
500	I-I
,	I-I
10	I-I
-	I-I
s	I-I
video	I-I
clips	I-I
demonstrating	O
patient	B-I
-	I-I
centered	I-I
skills	I-I
in	O
various	O
ways	O
.	O

Four	B-P
clinician	I-P
members	I-P
of	I-P
the	I-P
American	I-P
Academy	I-P
of	I-P
Family	I-P
Physicians	I-P
National	I-P
Research	I-P
Network	I-P
participated	O
by	O
enrolling	O
194	B-P
patients	I-P
into	O
a	O
randomized	O
patient	O
trial	O
and	O
29	B-P
physicians	I-P
into	O
a	O
non	O
-	O
randomized	O
clinician	O
trial	O
of	O
respective	O
interventions	O
.	O

All	O
participants	O
completed	O
baseline	O
and	O
follow	B-O
-	I-O
up	I-O
self	I-O
-	I-O
report	I-O
measures	I-O
of	O
visit	B-O
communication	I-O
and	O
satisfaction	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Promoting	O
physical	O
activity	O
in	O
patients	B-P
with	I-P
colon	I-P
adenomas	I-P
:	O
a	O
randomized	O
pilot	O
intervention	O
trial	O
.	O

METHODS	O
:	O
Sixteen	B-P
adults	I-P
with	I-P
adenomas	I-P
detected	I-P
and	I-P
removed	I-P
at	I-P
screening	I-P
colonoscopy	I-P
were	O
recruited	O
to	O
a	B-I
12	I-I
-	I-I
week	I-I
physical	I-I
activity	I-I
intervention	O
.	O

Participants	O
were	O
randomized	O
to	O
receive	O
a	B-C
standard	I-C
(	I-C
30	I-C
minutes	I-C
/	I-C
day	I-C
)	I-C
or	O
high	B-I
(	I-I
60	I-I
minutes	I-I
/	I-I
day	I-I
)	I-I
walking	I-I
program	I-I
.	O

Physical	B-O
activity	I-O
was	O
measured	O
via	O
blinded	B-O
pedometer	I-O
and	O
accelerometer	B-O
at	O
baseline	O
and	O
follow	O
-	O
up	O
.	O

Intervention	O
messages	O
focused	O
on	O
self	B-O
-	I-O
monitoring	I-O
using	O
pedometers	B-O
and	O
overcoming	B-O
barriers	I-O
to	I-O
engaging	I-O
in	I-O
physical	I-O
activity	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Localised	O
prostate	O
cancer	O
:	O
the	O
PREFERE	O
trial	O
]	O
.	O

METHODS	O
:	O
Based	O
on	O
the	O
discussions	O
of	O
the	O
Joint	O
Federal	O
Committee	O
(	O
G	O
-	O
BA	O
)	O
and	O
the	O
conceptual	O
work	O
of	O
the	O
MDS	O
,	O
the	O
Competence	O
Centre	O
Oncology	O
of	O
the	O
MDK	O
,	O
the	O
IQWIG	O
and	O
the	O
National	O
Association	O
of	O
Statutory	O
Health	O
Insurance	O
Funds	O
(	O
GKV	O
-	O
Spitzenverband	O
)	O
,	O
a	O
prospective	O
randomised	O
multicentre	O
trial	O
was	O
developed	O
comparing	O
the	O
four	O
treatments	O
actually	O
recommended	O
by	O
the	O
German	O
and	O
European	O
guidelines	O
for	O
localised	O
prostate	O
cancer	O
(	O
radical	B-I
prostatectomy	I-I
,	O
percutaneous	B-I
radiotherapy	I-I
and	O
permanent	B-I
seed	I-I
implantation	I-I

and	O
active	B-I
surveillance	I-I
)	O
allowing	O
a	O
rejection	O
of	O
one	O
or	O
two	O
treatment	O
options	O
.	O

-DOCSTART-	O

Title	O
:	O
Adjunctive	B-I
perampanel	I-I
for	O
refractory	O
partial	O
-	O
onset	O
seizures	O
:	O
randomized	O
phase	O
III	O
study	O
304	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
ClinicalTrials	O
.	O
gov	O
identifier	O
:	O
NCT00699972	O
)	O
.	O

Patients	B-P
(	I-P
?12	I-P
years	I-P
,	I-P
with	I-P
ongoing	I-P
seizures	I-P
despite	I-P
1	I-P
-	I-P
3	I-P
AEDs	I-P
)	I-P
were	O
randomized	O
(	O
1:1:1	O
)	O
to	O
once	B-I
-	I-I
daily	I-I
perampanel	I-I
8	O
mg	O
,	O
12	O
mg	O
,	O
or	O
placebo	B-C
.	O

Following	O
baseline	O
(	O
6	O
weeks	O
)	O
,	O
patients	O
entered	O
a	O
19	O
-	O
week	O
double	O
-	O
blind	O
phase	O
:	O
6	O
-	O
week	O
titration	O
(	O
2	O
mg	O
/	O
week	O
increments	O
to	O
target	O
dose	O
)	O
followed	O
by	O
a	O
13	O
-	O
week	O
maintenance	O
period	O
.	O

Percent	O
change	O
in	O
seizure	B-O
frequency	I-O
was	O
the	O
primary	O
endpoint	O
;	O
50	O
%	O
responder	O
rate	O
was	O
the	O
primary	O
endpoint	O
for	O
EU	O
registration	O
.	O

METHODS	O
:	O
This	O
study	O
provides	O
Class	O
I	O
evidence	O
that	O
once	O
-	O
daily	O
8	O
and	O
12	O
mg	O
doses	O
of	O
adjunctive	O
perampanel	O
are	O
effective	O
in	O
patients	O
with	O
uncontrolled	O
partial	O
-	O
onset	O
seizures	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
effects	O
of	O
ezetimibe	B-I
-	O
plus	O
-	O
statin	B-I
therapy	I-I
on	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
levels	O
as	O
compared	O
with	O
double	O
-	O
dose	O
statin	O
therapy	O
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
.	O

METHODS	O
:	O
Coronary	B-P
artery	I-P
disease	I-P
patients	I-P
whose	I-P
LDL	I-P
-	I-P
C	I-P
?	I-P
70	I-P
mg	I-P
/	I-P
dL	I-P
after	I-P
treatment	I-P
with	I-P
atorvastatin	I-P
10	I-P
mg	I-P
/	I-P
day	I-P
or	I-P
rosuvastatin	I-P
2	I-P
.	I-P
5	I-P
mg	I-P
/	I-P
day	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
ezetimibe	B-I
10	O
mg	O
/	O
day	O
+	O
statin	B-I
(	O
n	O
=	O
78	O
)	O
or	O
double	B-I
-	I-I
dose	I-I
statin	I-I
(	O
n	O
=	O
72	O
)	O
for	O
52	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
bexarotene	B-I
combined	I-I
with	I-I
psoralen	I-I
-	I-I
ultraviolet	I-I
A	I-I
(	I-I
PUVA	I-I
)	I-I
compared	O
with	O
PUVA	B-C
treatment	I-C
alone	I-C
in	O
stage	O
IB	O
-	O
IIA	O
mycosis	O
fungoides	O
:	O
final	O
results	O
from	O
the	O
EORTC	O
Cutaneous	O
Lymphoma	O
Task	O
Force	O
phase	O
III	O
randomized	O
clinical	O
trial	O
(	O
NCT00056056	O
)	O
.	O

METHODS	O
:	O
EORTC	O
21011	O
(	O
NCT	O
00056056	O
)	O
was	O
a	O
randomized	O
phase	O
III	O
study	O
comparing	O
combined	O
bexarotene	B-I
(	I-I
Targretin	I-I
(	I-I
	I-I
)	I-I
)	I-I
and	O
PUVA	B-I
vs	O
.	O

PUVA	B-C
alone	I-C
in	O
patients	B-P
with	I-P
stage	I-P
IB	I-P
and	I-P
IIA	I-P
mycosis	I-P
fungoides	I-P
(	I-P
MF	I-P
)	I-P
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
overall	I-O
response	I-O
rate	I-O
[	O
complete	B-O
clinical	I-O
response	I-O
(	I-O
CCR	I-O
)	I-O
plus	O
partial	B-O
response	I-O
(	I-O
PR	I-O
)	I-O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Airway	O
responses	O
and	O
inflammation	O
in	O
subjects	B-P
with	I-P
asthma	I-P
after	O
four	B-I
days	I-I
of	I-I
repeated	I-I
high	I-I
-	I-I
single	I-I
-	I-I
dose	I-I
allergen	I-I
challenge	I-I
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
27	I-P
patients	I-P
aged	I-P
18	I-P
to	I-P
40	I-P
years	I-P
with	I-P
positive	I-P
skin	I-P
-	I-P
prick	I-P
tests	I-P
and	I-P
mild	I-P
asthma	I-P
underwent	O
repetitive	B-I
high	I-I
-	I-I
dose	I-I
allergen	I-I
challenges	I-I
with	O
household	O
dust	O
mites	O
for	O
four	O
consecutive	O
days	O
.	O

Pulmonary	B-O
function	I-O
and	O
exhaled	B-O
NO	I-O
were	O
measured	O
at	O
every	O
visit	O
.	O

Induced	B-O
sputum	I-O
was	O
analysed	O
before	O
and	O
after	O
the	O
allergen	O
challenges	O
for	O
cell	B-O
counts	I-O
,	O
ECP	B-O
,	O
IL	B-O
-	I-O
5	I-O
,	O
INF	B-O
-	I-O
?	I-O
,	O
IL	B-O
-	I-O
8	I-O
,	O
and	O
the	B-O
transcription	I-O
factor	I-O
Foxp3	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Improving	O
RBC	O
K	O
transport	O
and	O
hemoglobin	O
-	O
O2	O
binding	O
by	O
amiloride	B-I
:	O
A	O
novel	O
therapeutic	O
approach	O
for	O
reversion	O
of	O
angina	O
and	O
myocardial	O
ischemia	O
in	O
coronary	O
heart	O
diseases	O
.	O

Coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
is	O
the	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
across	O
the	O
entire	O
world	O
,	O
in	O
which	O
reversion	O
of	O
angina	O
or	O
improvement	O
of	O
ECG	O
remains	O
an	O
unrealistic	O
therapeutic	O
option	O
for	O
most	O
patients	O
,	O
suggesting	O
that	O
microvascular	O
dysfunction	O
or	O
impaired	O
oxygen	O
delivery	O
might	O
be	O
critical	O
factors	O
in	O
CHD	O
.	O

This	O
research	O
article	O
,	O
thus	O
presents	O
the	O
rationale	O
basis	O
,	O
clinical	O
and	O
experimental	O
,	O
for	O
the	O
first	O
therapeutic	O
innovation	O
addressing	O
the	O
role	O
of	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
H	O
/	O
K	O
and	O
O2	O
/	O
CO2	O
exchanges	O
in	O
CHD	O
.	O

It	O
is	O
followed	O
by	O
a	O
randomized	O
single	O
-	O
blind	O
trial	O
of	O
Amiloride	O
and	O
Optimal	O
Medical	O
Therapy	O
(	O
OMT	O
,	O
n=35	O
cases	O
)	O
vs	O
OMT	O
alone	O
(	O
n=35	O
cases	O
)	O
in	O
patients	O
having	O
angina	O
,	O
ST	O
-	O
T	O
alteration	O
and	O
a	O
defective	O
RBC	O
-	O
K	O
transport	O
.	O

All	O
patients	O
had	O
serial	O
clinical	O
evaluation	O
,	O
Ion	O
Transport	O
Studies	O
,	O
ECGs	O
and	O
non	O
-	O
invasive	O
aortic	O
waveform	O
and	O
cardiovascular	O
hemodynamic	O
recordings	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
SAS	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
brief	I-I
Early	I-I
Start	I-I
Denver	I-I
model	I-I
(	I-I
ESDM	I-I
)	I-I
-	I-I
based	I-I
parent	I-I
intervention	I-I
on	O
toddlers	B-P
at	I-P
risk	I-P
for	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
controlled	O
trial	O
involving	O
98	B-P
children	I-P
and	I-P
families	I-P
was	I-P
carried	I-P
out	I-P
in	I-P
three	I-P
different	I-P
sites	I-P
investigating	O
the	B-O
efficacy	I-O
of	O
a	B-I
parent	I-I
delivery	I-I
of	I-I
the	I-I
Early	I-I
Start	I-I
Denver	I-I
model	I-I
(	I-I
P	I-I
-	I-I
ESDM	I-I
)	I-I
,	O
which	O
fosters	O
parental	O
use	O
of	O
a	O
child	O
-	O
centered	O
responsive	O
interaction	O
style	O
that	O
embeds	O
many	O
teaching	O
opportunities	O
into	O
play	O
,	O
compared	O
to	O
community	B-C
treatment	I-C
as	I-C
usual	I-C
.	O

Assessments	O
were	O
completed	O
at	O
baseline	O
and	O
12	O
weeks	O
later	O
,	O
immediately	O
after	O
the	O
end	O
of	O
parent	O
coaching	O
sessions	O
.	O

-DOCSTART-	O

Title	O
:	O
Potential	O
effect	O
of	O
the	O
risk	O
of	O
ovarian	B-I
cancer	I-I
algorithm	I-I
(	I-I
ROCA	I-I
)	I-I
on	O
the	O
mortality	O
outcome	O
of	O
the	O
Prostate	O
,	O
Lung	O
,	O
Colorectal	O
and	O
Ovarian	O
(	O
PLCO	O
)	O
trial	O
.	O

METHODS	O
:	O
We	O
investigated	O
whether	O
having	O
had	O
used	O
ROCA	B-I
in	O
PLCO	O
could	O
have	O
,	O
under	O
optimal	O
assumptions	O
,	O
resulted	O
in	O
a	B-O
significant	I-O
mortality	I-O
benefit	I-O
by	O
applying	O
ROCA	B-I
to	O
PLCO	O
CA125	O
screening	O
values	O
.	O

A	O
best	O
-	O
case	O
scenario	O
assumed	O
that	O
all	O
cancers	O
showing	O
a	O
positive	O
screen	O
result	O
earlier	O
with	O
ROCA	B-I
than	O
under	O
the	O
PLCO	O
protocol	O
would	O
have	O
avoided	O
mortality	B-O
;	O
under	O
a	O
stage	O
-	O
shift	O
scenario	O
,	O
such	O
women	O
were	O
assigned	O
survival	O
equivalent	O
to	O
Stage	O
I	O
/	O
II	O
screen	O
-	O
detected	O
cases	O
.	O

-DOCSTART-	O

Title	O
:	O
End	O
-	O
expiratory	O
lung	O
volume	O
recovers	O
more	O
slowly	O
after	O
closed	B-I
endotracheal	I-I
suctioning	I-I
than	O
after	O
open	B-I
suctioning	I-I
:	O
a	O
randomized	O
crossover	O
study	O
.	O

METHODS	O
:	O
Randomized	O
crossover	O
study	O
examining	O
20	B-P
patients	I-P
postcardiac	I-P
surgery	I-P
.	O

CS	B-I
and	O
OS	B-I
were	O
performed	O
in	O
random	O
order	O
,	O
30	O
minutes	O
apart	O
.	O

Lung	B-O
impedance	I-O
was	O
measured	O
during	O
suction	O
,	O
and	O
end	B-O
-	I-O
expiratory	I-O
lung	I-O
impedance	I-O
was	O
measured	O
at	O
baseline	O
and	O
postsuctioning	O
using	O
electrical	O
impedance	O
tomography	O
.	O

Oximetry	B-O
,	O
partial	B-O
pressure	I-O
of	I-O
oxygen	I-O
in	I-O
the	I-O
alveoli	I-O
/	I-O
fraction	I-O
of	I-O
inspired	I-O
oxygen	I-O
ratio	I-O
and	O
compliance	B-O
were	O
collected	O
.	O

